Can neuroblastoma in children be cured?

Pediatric neuroblastoma (Neuroblastoma) is a common malignant tumor in children, mostly seen in children under the age of 5. It originates in the sympathetic nervous system and usually occurs in the adrenal glands, abdomen, or chest. The cure rate depends on the tumor stage, risk stratification, patient age, and tumor biology.

For low-risk and intermediate-risk neuroblastoma, the cure rate is relatively high, reaching 90% or more. These patients usually achieve good results with surgery to remove the tumor and chemotherapy. High-risk neuroblastoma is difficult to treat and requires multimodal comprehensive treatment, including high-dose chemotherapy, surgery, radiotherapy, autologous stem cell transplantation, and immunotherapy. Even under optimal treatment, long-term survival rates for high-risk patients are approximately 40%-50%.

In recent years, immunotherapy for high-risk neuroblastoma (such as anti-GD2 monoclonal antibodyDinutuximab) has significantly improved patient survival rates. In addition, targeted therapy and molecular typing research also provide new directions for disease treatment. Key factors affecting cure include stage (I stage, II stage has a better prognosis), age (patients under 18 months have a better prognosis) and tumor molecular characteristics (such as MYCN amplification indicates a worse prognosis).

To sum up, most low-risk and intermediate-risk neuroblastomas can be cured, while high-risk patients are more difficult to cure. However, with the continuous development of new treatments, the survival rate of some high-risk patients has been significantly improved. Early diagnosis and standardized treatment are particularly important to improve prognosis.

(Click to view the introduction of drugs for treating neuroblastoma in children. For specific drug details, please click for one-to-one consultation.)

xa0

ReferenceInformation：https://www.cancer.gov/types/neuroblastoma